BioCentury
ARTICLE | Clinical News

PSI-7977: Phase II started

March 5, 2012 8:00 AM UTC

Medivir AB (SSE:MVIR B, Huddinge, Sweden) disclosed in its 4Q11 earnings that Janssen R&D Ireland (formerly Tibotec Pharmaceuticals Ltd.) began an open-label, U.S. Phase II trial to evaluate 150 mg TMC435 daily in combination with 400 mg GS-7977 daily with or without ribavirin in about 180 patients with chronic HCV genotype 1 infection who were null responders to peginterferon and ribavirin. Last year, Pharmasset Inc. partnered with Tibotec, part of Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.), to evaluate a combination of the companies' HCV candidates in a Phase II trial. Gilead acquired Pharmasset earlier this year (see BioCentury, Jan. 23). Janssen R&D Ireland has ex-Nordic rights to develop and commercialize TMC435 from Medivir. ...